Clinical Trial

Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 28, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this study is to investigate whether long-term oral administration of Staphylococcus albicans tablets can significantly reduce the number of acute exacerbations in patients with bronchiectasis. Secondary objective is to explore whether long-term oral administration of Staphylococcus albicans tablets can reduce the risk of hospitalization in patients with bronchiectasis and whether it can improve the quality of life of patients. Other purpose is to explore the regulatory effect of long-term oral administration of Staphylococcus albicans tablets on the immune function of patients with bronchiectasis.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-06-01; most recent amendment 2025-02-26.
Status change: Not Yet Recruiting → Recruiting 2022-09-22
Trial Details
NCT Number NCT05407792
Lead Sponsor Qianfoshan Hospital
Conditions Bronchiectasis
Enrollment 134 participants
Start Date 2022-06-06
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-28